Introduction {#s1}
============

Fanconi anemia (FA) is a devastating childhood syndrome that results in bone marrow failure, leukemia and head and neck cancers ([@bib12]; [@bib2]). FA is caused by inheritance of one of 22 dysfunctional FA genes (FANCA-FANCW) ([@bib61]). Absence of any one member of the pathway causes genome instability during DNA replication, which results in mutagenic (cancer-causing) DNA damage and hypersensitivity to chemotherapeutic (normal and cancer-killing) DNA damage ([@bib9]). Central to the FA pathway is the conjugation of ubiquitin to FANCI:FANCD2 (ID2) complexes ([@bib67]). ID2 monoubiquitination is critical to prevention of bone marrow failure in FA, but it is currently unknown how ID2-ub differs in its function to ID2. Several proteins have been proposed to specifically bind FANCI^Ub^ or FANCD2^Ub^ but not the un-ubiquitinated proteins ([@bib56]; [@bib25]). For example, FAN1 nuclease was proposed to interact with FANCD2^Ub^ via its ubiquitin-binding domain (UBZ) ([@bib56]), whereas recruitment of SLX4 endonuclease to the interstrand crosslink site was shown to be dependent on FANCD2 ubiquitination ([@bib23]). However, support for these interactions is limited to analysis of ubiquitination-deficient (K \> R) mutants, rather than evidence for direct ubiquitin-mediated protein interactions.

The retention of FANCD2 in chromatin foci is dependent on its monoubiquitination by a 'core complex' of Fanconi anemia proteins ([@bib67]). FANCI and the FA core complex are required to generate FANCD2-foci that mark the location of double strand breaks, stalled replication forks and R-loops ([@bib62]; [@bib53]; [@bib71]) in the nucleus, and protect nascent DNA at these sites from degradation by cellular nucleases ([@bib52]). The ubiquitinated form of FANCD2, and also its ubiquitinated partner protein FANCI, become resistant to detergent and high-salt extraction from these foci ([@bib55]; [@bib38]), leading to speculation about the existence of a chromatin anchor or altered DNA binding specificity post-monoubiquitination ([@bib29]).

A recent electron microscopy study revealed a DNA interacting domain that is required for FANCI:FANCD2 binding to DNA ([@bib26]). The crystal structure of the non-ubiquitinated FANCI:FANCD2 shows that the monoubiquitination sites of FANCI:FANCD2 are buried and therefore inaccessible in the dimer interface of the complex ([@bib22]), suggesting that DNA binding might be required to expose the ubiquitin binding sites. Based on biochemical analyses, non-ubiquitinated FANCI and FANCD2 preferentially bind to branched DNA molecules which mimic DNA replication and repair intermediates ([@bib29]; [@bib28]; [@bib43]); however, how that activates monoubiquitination of FANCI:FANCD2 remains poorly understood. DNA is a cofactor for maximal ubiquitination ([@bib29]; [@bib66]), as is phosphorylation by the ATR kinase ([@bib60]; [@bib20]).

Here, we have reconstituted the FA pathway using recombinant FA core complex and fluorescently labeled DNA oligomer substrates. We show that once monoubiquitinated, FANCI:FANCD2 forms a tight interaction with double-stranded containing DNA. We report the successful purification of monoubiquitinated FANCI:FANCD2 complex bound to DNA using an Avi-ubiquitin construct, and show that the monoubiquitination does not promote any new protein:protein interactions with other factors in vitro. Instead, we reveal a new role of monoubiquitinated FANCI:FANCD2 in forming higher order structures and demonstrate how monoubiquitinated FANCI:FANCD2 interacts with DNA to initiate DNA repair. Our work uncovers the molecular function of the pathogenetic defect in most cases of FA.

Results {#s2}
=======

Monoubiquitination does not promote association of FANCI:FANCD2 with a panel of proteins previously hypothesized to bind the ubiquitinated form {#s2-1}
-----------------------------------------------------------------------------------------------------------------------------------------------

Mono-ubiquitinated FANCI:FANCD2 (henceforth I^Ub^D2^Ub^) is the active form of the complex in repair of DNA damage. Many previous studies have speculated about the existence of DNA repair proteins that specifically associate with I^Ub^D2^Ub^. A summary of these proteins is presented in [Table 1](#table1){ref-type="table"}. Using recombinant ID2 or I^Ub^D2^Ub^ prepared by Avi-ubiquitin purification method ([@bib59]), we sought to directly compare the binding of this panel of ID2-associated proteins. Each of the partner proteins was expressed using reticulocyte extracts ([Figure 1a](#fig1){ref-type="fig"}), and the majority bound to the ID2 complex as predicted based on previously identified associations ([Figure 1b](#fig1){ref-type="fig"}). The strongest binding proteins in terms of fraction of protein recovered were SLX4, FAAP20, SMARCAD, FANCJ, PSMD4, SF3B1, MCM5 and BRE. Although SMARCAD and SF3B1 appeared 'sticky' in control experiments, recovery of these proteins was still enriched by FANCD2:FANCI beads compared to background. Luciferase protein was used as a control ^35^S-labeled prey-protein. Surprisingly, our main observation was that none of the proteins showed any increased affinity for I^Ub^D2^Ub^ over ID2 ([Figure 1d](#fig1){ref-type="fig"}).

###### List of proteins containing ubiquitin binding domain that are described or predicted to bind to ubiquitinated FANCD2.

  Protein    Function                 Domain             Reference
  ---------- ------------------------ ------------------ ------------
  FAN1       Nuclease                 UBZ4               ([@bib24])
  SLX4       Nuclease                 UBZ1               ([@bib25])
  FAAP20     FANCA partner            UBZ                ([@bib15])
  RAP80      BRCA1 partner            UIM                ([@bib4])
  SMARCAD1   Chromatin remodeler      CUE                ([@bib10])
  FANCJ      Helicase                 \-                 ([@bib44])
  PSMD4      Protease                 UIM                ([@bib21])
  SF3B1      RNA binding protein      UBZ                ([@bib39])
  TRIM25     E3 ligase                RING finger        ([@bib31])
  MCM5       CMG component            \-                 ([@bib31])
  BRE        BRCA1 partner            \-                 ([@bib68])
  BRCC       BRCA1 partner            \-                 ([@bib68])
  SNM1A      Nuclease                 UBZ                ([@bib72])
  CtIP\*     Nuclease activator       C2H2 zinc finger   ([@bib40])
  Rev1\*     Translesion polymerase   UBZ3               ([@bib37])

^\*^Indicates not tested in our experiments, because protein not produced in TnT system.

![Mono-ubiquitination does not alter interaction of FANCI:FANCD2 with DNA repair proteins.\
(**a**) ^35^S-labelled FAN1, SLX4, FAAP20, RAP80, SMARCAD, FANCJ, PSMD4, SF3B1, TRIM25, MCM5, BRE, BRCC, SNM1A or luciferase (control) inputs were expressed using reticulocyte extracts. (**b--c**) The inputs prepared from (**a**) were incubated with the indicated FLAG-ID2 (**b**) or FLAG-I^ub^D2^ub^ (**c**) followed by FLAG pull-down and elution. The complexes were subjected to SDS-PAGE, and radiolabelled proteins were detected by autoradiography (representative experiment of n = 2). (**d**) Quantification showing percentage of ID2, I^ub^D2^ub^ or FLAG resin binding to inputs.](elife-54128-fig1){#fig1}

Monoubiquitination clamps FANCI:FANCD2 on DNA {#s2-2}
---------------------------------------------

An alternative explanation for the observed increase in association between ID2 and its associated proteins after DNA damage is that I^Ub^D2^Ub^ has an increased affinity for DNA, which brings the protein into closer proximity to these partners. The majority of ID2 associated proteins are chromatin localized. In order to explore the stability of I^Ub^D2^Ub^ on DNA, we performed in vitro monoubiquitination reactions in the presence of IR-dye700 labeled 60 bp double-stranded DNA (dsDNA). As previously characterized ([@bib66]), we observed DNA-dependent appearance of monoubiquitinated forms of FANCD2 and FANCI when using recombinant FA core complex components ([Figure 2a--b](#fig2){ref-type="fig"}). ID2 monoubiquitination readily lead to DNA mobility shifts using EMSA (electromobility shift assay) even at low concentrations, but this was not observed for the unmodified (apo)-ID2 complex in the absence of the enzymatically active FA core complex, or when monoubiquitination-defective K-to-R mutants of ID2 were used in the reaction ([Figure 2c](#fig2){ref-type="fig"}, lanes 2--4).

![Monoubiquitination locks FANCI:FANCD2 on DNA.\
(**a**) Schematic of the electrophoretic mobility shift assay (EMSA) using IRDye-700 labeled dsDNA. (**b**) Coomassie stained SDS-PAGE gel showing monoubiquitination of FANCI:FANCD2 using recombinant FA core complex and IR-dye700 labeled dsDNA. 25, 50 and 100 nM of ID2 or I^KR^D2^KR^ were incubated with 25 nM of the IR-dye700 dsDNA for 90 min. The respective percentage of FANCI or FANCD2 monoubiquitination were calculated and shown under SDS-PAGE gel. (**c**) Monoubiquitination reactions from (**b**) were resolved on 6% native PAGE gel for EMSA analysis. The percentage of ID2 binding to DNA was calculated and shown under native PAGE gel.](elife-54128-fig2){#fig2}

Previously, we and others showed that various different dsDNA-containing structures could robustly stimulate ID2 monoubiquitination ([@bib29]; [@bib66]; [@bib49]), but that single-stranded DNA (ssDNA) does not. To determine if monoubiquitinated ID2 had increased affinity for other dsDNA containing structures, we repeated the monoubiquitination reactions in the presence of different IR-dye700 labeled DNA structures. Interestingly, non-ubiquitinated ID2 also exhibited high affinity toward 3' flap DNA structure (similar to a replication fork stalled on the lagging strand), which has been previously observed ([@bib26]). The 3'-Flap structure, and each of the other dsDNA containing structures, led to increased ID2 monoubiquitination and increased retention of an EMSA shifted band ([Figure 3](#fig3){ref-type="fig"}). Conversely, ssDNA, which stimulates monoubiquitination more slowly ([@bib66]) but to similar levels at the long time point of this assay, did not cause an EMSA shift.

![Monoubiquitinated FANCI:FANCD2 binds to any type of dsDNA.\
EMSA gels showing binding of monoubiquitinated or unmodified ID2 complex to different oligo-based DNA substrates. Above each panel, a schematic representing the tested DNA substrate is shown. 25, 50 and 100 nM of ID2 or I^KR^D2^KR^ were incubated with 25 nM of the indicated DNA substrate and the protein:DNA complexes were resolved on 6% PAGE gels (top). The percentage of DNA binding was calculated and shown under each EMSA gel. Coomassie stained SDS-PAGE gel (bottom) showing the ubiquitination reactions used in the EMSA. The percentage of FANCD2 monoubiquitination was calculated and shown under each SDS-PAGE gel.](elife-54128-fig3){#fig3}

Both FANCI^ub^ and FANCD2^ub^ are associated with a 'clamped' protein:DNA complex {#s2-3}
---------------------------------------------------------------------------------

Previous studies reported that monoubiquitination of ID2 complex may lead to dissociation of the heterodimer to its individual subunits, as measured by loss of co-immunoprecipitation of FANCI with FANCD2 (40, 41). In contrast, we did not observe any Ub-mediated dissociation of ID2 in vitro. First, western blotting of the EMSA gels confirmed that the gel shifted DNA band contains both FANCI and FANCD2 proteins ([Figure 4a](#fig4){ref-type="fig"}). Second, FANCI^Ub^ still co-immunoprecipitated with FANCD2^Ub^ at the plateau of the in vitro ubiquitination reaction ([Figure 4b](#fig4){ref-type="fig"}).

![FANCD2 monoubiquitination is sufficient for FANCI:FANCD2 locking to DNA, but stimulated by FANCI monoubiquitination.\
(**a**) Western blots of the EMSA gels containing 50, 100 and 200 nM of I^ub^D2^ub^, ID2 or I^KR^D2^KR^ in the presence of 25 nM IRDye-700 labeled dsDNA (red). Left panels correspond to anti-FANCI antibody (green) and right panels correspond to anti-FANCD2 antibody (green) (**b**) StrepII affinity purification of mono-ubiquitinated (+ATP) and non-ubiquitinated ID2 (-ATP). (**c**) EMSA gels (top) and western blots (bottom) showing the monoubiquitination of 25, 50 and 100 nM I^WT^D2^WT^, I^KR^D2^WT^, I^WT^D2^KR^ or I^KR^D2^KR^ in the presence of 25 nM IRDye-700 labeled dsDNA. (**d**) Western blots of the EMSA gels showing monoubiquitination of 50, 100 and 200 nM I^WT^D2^WT^, I^KR^D2^WT^, I^WT^D2^KR^ or I^KR^D2^KR^ in the presence of 25 nM IRDye-700 labeled dsDNA. FANCI (left, green) and FANCD2 (right, green) remained bound to IRDye-700 labeled DNA (red) after mono-ubiquitination.](elife-54128-fig4){#fig4}

To determine the contribution of each of FANCD2^Ub^ and FANCI^Ub^ to the clamping of I^Ub^D2 ^Ub^ complex to DNA, we used ubiquitination-deficient (KR) mutants in the ubiquitination reaction. FANCI^KR^:FANCD2^WT^ or FANCI^WT^:FANCD2^KR^ mutant results in decrease in EMSA shift, and FANCI^KR^:FANCD2^KR^ did not bind to DNA ([Figure 4c](#fig4){ref-type="fig"}). However, this retention on DNA correlated with the extent of FANCD2 monoubiquitination retained by these mutant complexes. Western blotting the EMSA gels confirmed that both FANCD2 and FANCI are found in the EMSA shifted product, although in higher amounts when both proteins are capable of being monoubiquitinated ([Figure 4d](#fig4){ref-type="fig"}).

Mutant forms of ubiquitin can still clamp ID2 onto DNA {#s2-4}
------------------------------------------------------

We postulated that the altered affinity for DNA induced by monoubiquitination must result from either a conformational change in the ID2 heterodimer after monoubiquitination, or participation of the conjugated ubiquitin directly in protein:DNA or protein:protein binding. To help distinguish these possibilities, we utilized mutants of ubiquitin that have previously been shown to mediate the known protein:ubiquitin or protein:DNA interactions in other ubiquitinated protein interactions ([Figure 5a](#fig5){ref-type="fig"}; [@bib18]). Each of these Ub mutants were conjugated to ID2 by the FA core complex with similar efficiency ([Figure 5b](#fig5){ref-type="fig"}) and their clamping onto DNA was then measured. Mutations in surface patch 1 (F4A, D58A), surface patch 2 (I44A, V70A), a DNA binding residue (K11R) or a tail mutant (L73P) had no apparent effect on DNA clamping ([Figure 5c](#fig5){ref-type="fig"}). This result suggests that no canonical surface or region of ubiquitin is critical for DNA clamping of ID2, and instead ubiquitin conjugation to ID2 probably induces a conformational rearrangement of the heterodimer.

![Mutations in different ubiquitin patches do not affect ID2 mono-ubiquitination or DNA binding.\
(**a**) Crystal structure of ubiquitin with ubiquitin mutant sites depicted (PDB: 1UBQ). Hydrophobic binding pockets are indicated in blue and pink. (**b**) Western blots showing the time course ubiquitination assays of ID2 using wild-type ubiquitin or ubiquitin F4A, V70A, I44A, D58A, K11R and L73P mutants. (**c**) EMSA gels showing 25, 50 and 100 nM monoubiquitinated ID2 binding to 25 nM IRDye-700 dsDNA using various ubiquitin mutants (top). Western blots of ID2 ubiquitination products were shown at the bottom and the percentage of FANCI and FANCD2 ubiquitination were shown at the bottom of each western blot panel.](elife-54128-fig5){#fig5}

Purification of monoubiquitinated FANCI:FANCD2 complex bound to dsDNA reveals a filamentous architecture {#s2-5}
--------------------------------------------------------------------------------------------------------

In order to examine the architecture of purified recombinant I^Ub^D2^Ub^ complex in the presence of dsDNA plasmid, we utilized a recombinant Avi-tag ubiquitin construct containing a 3C protease site between the biotinylated Avi-tag and the N-terminus of ubiquitin ([@bib59]; [Figure 6a](#fig6){ref-type="fig"}). This tagged ubiquitin is incorporated onto FANCI:FANCD2 by the FA core complex, allowing Avidin-Sepharose purification of monoubiquitinated ID2 that is then eluted by 3C protease cleavage. We recovered monoubiquitinated FANCI:FANCD2 complex only when FANCI is monoubiquitinated, suggesting that the N-terminus of D2-attached ubiquitin may be buried within the di-ubiquitinated complex, but the N-terminus of ubiquitin attached to FANCI is accessible for avidin binding ([Figure 6b](#fig6){ref-type="fig"}).

![Mono-ubiquitinated FANCI:FANCD2 complex assemble into filament-like arrays.\
(**a**) Schematic of purification of monoubiquitinated FANCI:FANCD2 using Avi-ubiquitin. (**b**) Coomassie stained SDS-PAGE gel (top) and western blots (bottom) showing the purification of monoubiquitinated FANCI:FANCD2 complex eluted using PreScission protease (lanes 1--7) compared to without PreScission protease (lanes 8--14). (**c--e**) Representative negative-stained EM image of purified FANCI^ub^:FANCD2^ub^ complex bound to 2.7 kb plasmid, unmodified FANCI:FANCD2 incubated with 2.7 kb plasmid and unmodified FANCI:FANCD2 complex. Pseudo-colored regions are shown to highlight particular filament-like arrays in FANCI^ub^:FANCD2^ub^ but not other samples.](elife-54128-fig6){#fig6}

Using this purified protein, we compared FANCI^ub^:FANCD2^ub^ to unmodified FANCI:FANCD2 using electron microscopy (EM). Surprisingly, we observed that FANCI^ub^:FANCD2^ub^ forms filament-like arrays when bound to dsDNA plasmid ([Figure 6c](#fig6){ref-type="fig"}). Such arrays were not observed in the unmodified FANCI:FANCD2 protein preparation in the absence of presence of plasmid DNA, nor in previous investigations of human or *Xenopus* FANCI:FANCD2 complexes studied by EM ([Figure 6d--e](#fig6){ref-type="fig"} and [@bib58]; [@bib26]; [@bib30]).

When smaller DNA molecules were used as the substrate for ID2 binding, we either observed no filament-like structures (60 bp, [Figure 7a](#fig7){ref-type="fig"}) or shorter filament-like structures (150 bp, [Figure 7b](#fig7){ref-type="fig"}) compared to structures that were on average 7-8x longer than the characteristic double saxophone structure of ID2 heterodimer in the non-ubiquitinated state ([Figure 7c](#fig7){ref-type="fig"}).

![Monoubiquitinated FANCI:FANCD2 assembles into filamentous arrays along the length of dsDNA.\
(**a--d**) Representative EM image of monoubiquitinated FANCI:FANCD2 bound to (**a**) 60 bp dsDNA, (**b**) 150 bp dsDNA, (**c**) 2.7 kb dsDNA, and (**d**) 2.7 kb dsDNA and Benzonase-treated. Scale bar, 100 nm. Arrows indicate formation of 1--2 ID2 array; boxes indicate multiple ID2 arrays. (**e**) Representative 2D class average of ID2. Views of the side and top of ID2 are shown, framed in blue for comparison. (**f**) Representative 2D class average of I^ub^D2^ub^ bound to 60 bp DNA. Views of the side and top of I^ub^D2^ub^ are shown, framed in red for comparison. (**g--h**) Example comparison of the length (y) and width (x) of class average images ID2 and I^ub^D2^ub^ (likely an overestimate, because uranyl formate staining increases apparent particle size).](elife-54128-fig7){#fig7}

The observation that array length correlated with the size of DNA available for ID2 binding strongly suggested that the association between heterodimer subunits in the array was DNA-mediated. To test whether the array of I^ub^D2^ub^ is also dependent upon binding to the same DNA molecule, we examined the plasmid-stimulated ubiquitination reaction products after treatment with the non-specific endonuclease, Benzonase. It is apparent from EM images that addition of Benzonase breaks the long arrays formed by I^ub^D2^ub^ complex into very short or heterodimer-sized units ([Figure 7d](#fig7){ref-type="fig"}). This finding is consistent with Benzonase cleaving exposed DNA between I^ub^D2^ub^ units, leading to destabilization of the filamentous arrays. Together our results show that, in vitro, ubiquitination of ID2 leads to a ubiquitin- and DNA- stabilized filament-like structure.

Single I^ub^D2^ub^ heterodimers on short 60 bp DNA have an altered architecture {#s2-6}
-------------------------------------------------------------------------------

Due to variability in the length and shape of filament-like I^ub^D2^ub^ structures on longer DNA molecules we have not been able to uncover the shape or subunit rearrangement of the individual units of the arrays because attempts to class average arrays failed due to a lack of order. However, examination of I^ub^D2^ub^ purified together with short 60 bp DNA allowed us to collect sufficient images of individual particles for analysis. These particles were similar in size to non-ubiquitinated ID2, but it is clear from individual molecule and class average views that the I^ub^D2^ub^ complex forms a distinct architecture from that of ID2 ([Figure 7e--f](#fig7){ref-type="fig"}). In particular, the overall shape of individual particles and their class averages reveal a twisting that repositions the solenoid arms of one or both of the subunits bringing them into closer proximity. The conformational change induced appears to reduce the size of ID2 in one direction (x vs y) but not the other ([Figure 7g--h](#fig7){ref-type="fig"}), similar to that predicted in a previously proposed model that placed DNA in a channel between FANCI and FANCD2 post DNA binding ([@bib29]). These images support the view that monoubiquitination induces a conformational change in the ID2 complex that clamps it upon DNA.

Discussion {#s3}
==========

The protection of stalled forks by DNA repair factors is essential for proper DNA replication and the maintenance of genome stability. The primary mechanism of replication fork stabilization at interstrand crosslinks, and other replication blocking damage, utilizes the proteins of the FA-BRCA DNA repair pathway. Monoubiquitination of FANCI:FANCD2 by the FA core complex is the central event in this pathway. Here, we showed that monoubiquitination directly clamps the ID2 complex onto double-stranded DNA, and promotes a filament-like coating of long DNA molecules. This finding answers a long-standing question about the nature of the biochemical reaction that is absent in the majority of patients with FA ([@bib70]; [@bib14]).

'Fork protection' involves (i) exclusion of cellular nucleases such as MRE11 and DNA2 from the stalled DNA replication fork, and (ii) specific recruitment of other factors that are able to restart DNA replication ([@bib52]; [@bib65]; [@bib33]). The role of nuclease exclusion seems most important because inhibition of either of two nucleases, MRE11 or DNA2, can significantly alleviate the sensitivity of FA-BRCA mutant cells to replication stalling agents ([@bib52]; [@bib65]). But in many studies, specific association of various repair factors with I^Ub^D2^Ub^ compared to ID2 have been described. These proteins mostly contain ubiquitin-binding domains, providing an impetus for the recruitment-based hypothesis (summary and references in [Table 1](#table1){ref-type="table"}). However, because these previous studies focused on use of ubiquitination-deficient mutants, they could not address the underlying question of whether ubiquitin on either FANCI, FANCD2 or both proteins directly mediated the interaction. Now, we have shown that none of these proteins specifically bind recombinant purified I^Ub^D2^Ub^ compared to ID2. This finding was unexpected, and included proteins such as SLX4 (FANCP), MCM5, and FAN1, which have a demonstrated and essential role in the FA-pathway ([@bib67]; [@bib31]; [@bib32]).

Instead, our data provide direct evidence that ID2 undergoes a conformational change after monoubiquitination, that leads to it becoming clamped on double-stranded DNA. It is likely that in previous cell-based experiments specific interaction between SLX4 and FAN1 with FANCD2 but not FANCD2^K561R^ was observed because FANCD2^K561R^ does not become clamped on DNA, even in the presence of active FA core complex. This finding is supported by the observation that FANCD2^K561R^ also does not becomes chromatin localized at damage sites even after extensive DNA damage ([@bib34]). We propose that I^Ub^D2^Ub^ does not demonstrate restricted interaction with any specific protein partner. None-the-less, its retention in chromatin after ubiquitination would be much more likely to bring the complex into proximity of these other DNA repair factors, where it could still influence their activity.

Clamping onto DNA occurs through a ubiquitin-mediated conformational change in the ID2 complex. A ubiquitin binding-domain (UBD) in FANCD2 has previously been shown necessary for the retention of the protein in the chromatin faction, and for strong binding to FANCI ([@bib46]). This UBD domain sits in the FANCD2 structure opposite to where ubiquitin is likely to reside after its conjugation on to FANCI by the FA core complex, and most likely mediates the clamping function and conformational rearrangement. A high-resolution cryo-EM structure of chicken ID2^Ub^ published by Alcón et al alongside our study ([@bib1]), also uncovered a conformational rearrangement of ID2 that is then stapled in place by ubiquitin:UBD association. Other DNA-binding proteins such as histone H2A show an increased association with DNA after monoubiquitination ([@bib75]) and monoubiquitination also increases the DNA occupancy of transcription factors such as FOXO4 and CIITA ([@bib13]). It is possible that ubiquitin to UBD mediated clamping is a general mechanism of protein:DNA target stabilization.

I^Ub^D2^Ub^ clamped in nucleoprotein arrays {#s3-1}
-------------------------------------------

In addition to a conformational change in ID2 induced by monoubiquitination (that has also been concurrently discovered and reported by the Pavletich, Walden and Passmore labs [@bib1]; [@bib69]; [@bib47]) we found that monoubiquitinated I^Ub^D2^Ub^ formed large filament-like arrays when it was purified together with plasmid DNA, but not short 60 bp DNA fragments. Fourier Transformation of the EM images did not reveal clear evidence for layer lines, that are expected for fiber diffraction, so we expect that the I^Ub^D2^Ub^ is not a true filament. On average, the length of plasmid-associated structures is 7-8x (but up to 40x) that of that associated with 60 bp DNA. Larger or longer arrays may potentially be obscured from view because the purification strategy makes elution exponentially more difficult with increasing numbers of conjugated ubiquitin-molecules. Steps to remove 'aggregates' may have also inadvertently removed larger arrays. However, as the number of potential plasmid DNA binding sites for ID2 was in large excess the concentration of ID2 used to stimulate reaction, there appears to be some purpose to creation of these filamentous arrays. The modular nature of I^Ub^D2^Ub^ arrays suggests that I^Ub^D2^Ub^ binding to DNA is flexible and can adopt multiple conformations, akin to RPA binding and protecting ssDNA ([@bib74]).

There is evidence that I^Ub^D2^Ub^ clamped in nucleoprotein filaments exist in cells. Antibodies against FANCD2 have long been used as a marker of double strand breaks, stalled replication forks and R-loops because the protein forms large, intensely stained foci during S-phase that are increased after treatment with DNA damaging agents ([@bib62]; [@bib53]; [@bib8]). We suspect that these intense foci are due to coating of DNA around damaged forks, potentially in filamentous arrays similar to those we observed by EM. Support for the large size and extent of DNA binding reflective of filamentous arrays also comes from chromatin immunoprecipitation and sequencing (ChIP-Seq) using anti-FANCD2 (13). FANCD2, and two other damage markers MRE11 and γH2AX, showed no specific localization in a bulk population of cells, but strongly localized adjacent to a Cas9-induced site-specific DNA break. Both γH2AX and FANCD2 produced a broad peak centered at the target site kilobases (kb) to megabases (mb) in length. In contrast, MRE11 is located within a very tight peak within \~100 bp of the break. Chromatin within 1--2 kb of the DSB showed reduced occupancy by γH2AX, consistent with dechromatinization around break sites ([@bib19]), but FANCD2 was present right up to the DSB. Accumulation of FANCD2 increases at the DSB early after cleavage, and accumulates more distant from the DSB progressively with time post-cleavage. This is suggestive of a polymerization of the FANCD2 signal away from the break site, as we hypothesize would occur for a protein that forms a growing array of molecules at broken DNA ([@bib71]). The conserved function of FANCD2 as a histone chaperone ([@bib50]; [@bib16]) may even be directly linked to displacement of nucleosomes as filamentous arrays extend into break-adjacent chromatin.

In this study, we also observed direct association of two ID2 heterodimers by co-immunopurification only after the protein becomes monoubiquitinated. This approach, if performed in cells, could be used to further delineate the mechanism and cellular factors required for the extension of I^Ub^D2^Ub^ arrays during fork protection. Of particular interest will be determining the role of BRCA1 in clamping and/or array extension. BRCA1:BARD1 was initially thought to be the E3 for FANCD2 monoubiquitination, because it co-immunoprecipitates FANCD2, and FANCD2 does not form nuclear foci after damage in BRCA1-deficient cells ([@bib44]). However, in various assays it was later shown that FANCD2 monoubiquitination does occur in BRCA1-deficient cells, but it is *uncoupled* from FANCD2 foci formation ([@bib21]; [@bib39]).

How would a clamped I^Ub^D2^Ub^ array mediate fork protection? {#s3-2}
--------------------------------------------------------------

Filamentous structures on DNA play a genome protective role in prokaryotes: eg DAN protein forms a rigid collaborative filament that reduces accessibility during anoxia ([@bib27]), while the *Vibrio cholera* protein ParA2 forms protective filamentous structures on DNA during segregation ([@bib17]). Structural characterization has demonstrated how these filaments function and, in the case of ParA2, can be targeted therapeutically ([@bib36]). The coating of ssDNA by RPA in eukaryotes, also protect DNA from the activity of nucleases, and directs the specific activity of others ([@bib7]; [@bib5]; [@bib42]). We propose that a FANCI^ub^:D2^ub^ arrays may have a similar stabilizing role on newly synthesized dsDNA at a stalled replication fork. This property would explain why stalled forks are prone to degradation in FA and BRCA patient cells ([@bib52]; [@bib65]). In particular, we hypothesize that filamentous DNA-clamped I^ub^:D2^ub^ could prevent access to DNA by MRE11 and DNA2 nucleases and prevent aberrant ligation of broken DNA to other parts of the genome by non-homologous end-joining.

Second, the tight binding of FANCI^ub^:D2^ub^ to dsDNA, when localized to stalled replication forks, may also prevent the branch migration of replication forks and inhibit their spontaneous or helicase-mediated reversal ([@bib41]). Reversed forks are the substrate for degradation by DNA2 and WRN nuclease activities, providing a hypothetical link between the activities of FANCD2-monoubiquitination and the nuclease activity of DNA2 and WRN ([@bib63]; [@bib54]).

Third, I^ub^:D2^ub^ arrays may also locally suppress non-homologous end-joining (NHEJ) factors, and/or delineate the newly synthesized chromatin from unreplicated regions during the promotion of templated repair processes such as homologous recombination. FANCD2, FANCI, and components of the FA core complex were identified amongst relatively few other factors, in a genome-wide screen for genes that promote templated repair over NHEJ ([@bib48]). Stabilization of RAD51 filaments, required for HR, is also an in vitro property of ID2 ([@bib51]), suggesting I^ub^:D2^ub^ filamentous arrays may exist adjacent to or coincident with RAD51 filaments in cells, in order to provide a polarity to the homologous recombination reaction without loss or gain of genomic sequences.

Role of FANCI-monoubiquitination {#s3-3}
--------------------------------

Fanci and Fancd2 have common and distinct functions in mouse models of Fanconi anemia ([@bib11]), while the double knockout of FANCI and FANCD2 has an unexpectedly distinct phenotype compared to single knockouts in human cells ([@bib64]). But FANCI^K523R^ expressing cells are less sensitive to DNA damage than FANCI knockout in human cells ([@bib55]), so what is the role of FANCI monoubiquitination? Previous studies demonstrated that FANCI monoubiquitination is always subsequent to FANCD2 monoubiquitination, both in cells ([@bib49]) and in biochemical assays ([@bib66]). FANCI also likely plays a role in recruiting the FA core complex to the substrate ([@bib3]). In this study, we show that FANCI-monoubiquitination is not necessary for clamping of the ID2 complex onto DNA ([Figure 4](#fig4){ref-type="fig"}). However, in vivo it is likely that FANCI monoubiquitination plays a critical role in regulating deubiquitination of the ID2 complex. FANCI recruits the deubiquitinating enzyme USP1:UAF1 ([@bib73]), which prevents trapping of monoubiquitinated FANCD2 at non-productive DNA damage sites, but only ID2^Ub^and not I^Ub^D2^Ub^ is a substrate ([@bib66]). It is also clear from our EM investigations that FANCI must play an important role in the structural integrity of I^Ub^D2^Ub^ filamentous arrays on DNA, possibly creating an asymmetry necessary for a specific polarity to array assembly.

Implications for understanding the deficiency of Fanconi anemia {#s3-4}
---------------------------------------------------------------

Onset of progressive bone marrow failure occurs at a median age of 7 in children with FA ([@bib2]). Almost all these patients lack FANCD2 and FANCI monoubiquitination, due to mutation in either *FANCD2* or *FANCI* or one of the nine other FANC proteins required for their monoubiquitination ([@bib67]). The importance of the monoubiquitin signal is highlighted by the observation that up to 20% of patients acquire somatic reversion of the inherited mutation in a fraction of blood cells ([@bib57]). These mutations restore monoubiquitination and prevent bone marrow failure. Our work suggests two potential strategies for treatment of FA: restoration of gene function, such as that which occurs in somatic revertants or, identification of novel mechanisms to stabilize an ID2:DNA-clamped complex for fork protection by ubiquitin-mediated or innovative means. New small molecule activators or inhibitors of ID2:DNA clamping could be therapeutics in FA or cancer-treatment. In vitro biochemistry has proven to be the most powerful tool in uncovering new functions of FANCD2-monoubiquination that had gone undiscovered for nearly 20 years. The approach is likely to be formidable in drugging the FA pathway in future studies.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                            Designation                                               Source or reference         Identifiers                                                              Additional information
  (species) or resource                                                                                                                                                                                   
  ---------------------------------------- --------------------------------------------------------- --------------------------- ------------------------------------------------------------------------ --------------------------------
  Recombinant DNA reagent (*X. laevis*)    pFastbac1-FLAG-xFANCI                                     ([@bib23])                                                                                           Gift from Puck Knipscheer

  Recombinant DNA reagent (*X. laevis*)    pFastbac1-StrepII-xFANCD2                                 ([@bib23])                                                                                           Gift from Puck Knipscheer

  Recombinant DNA reagent (*H. sapiens*)   pFL-EGFP-His-hFANCI                                       ([@bib59])                                                                                           

  Recombinant DNA reagent (*H. sapiens*)   pFastbac1-FLAG-hFANCD2^opt^                               ([@bib59])                  RRID:[Addgene\_ 134904](https://scicrunch.org/resolver/Addgene_134904)   Gift from Angelos Constantinou

  Recombinant DNA reagent (*H. sapiens*)   pFL/pSPL-EGFP-FLAG-B-L-100                                ([@bib66])                                                                                           Codon optimized FANCB

  Recombinant DNA reagent (*H. sapiens*)   pFL-MBP-C-E-F                                             ([@bib66])                                                                                           

  Recombinant DNA reagent (*H. sapiens*)   pGEX-KG-GST-UBE2T                                         ([@bib66])                                                                                           Codon optimized

  Recombinant DNA reagent (*E. coli*)      pet16b-Avi-ubiquitin_rbs_BirA                             ([@bib59])                  RRID:[Addgene_134897](https://scicrunch.org/resolver/Addgene_134897)     

  Recombinant DNA reagent (*E. coli*)      pSRK2706-GST-HRV-3Cprotease                               ([@bib45])                  RRID:[Addgene_78571](https://scicrunch.org/resolver/Addgene_78571)       A gift from David Waugh

  Recombinant DNA reagent (*E. coli*)      pUC19 plasmid                                             New England BioLabs         N3041S                                                                   

  Strain, strain background (*E. coli*)    BL21 (DE3)                                                Agilent Technologies        200131                                                                   

  Cell line (*Spodoptera frugiperda*)      *Sf*9                                                     Thermo Fisher Scientific    RRID:[CVCL_0549](https://scicrunch.org/resolver/CVCL_0549)               Maintained in Sf-900 II SFM

  Cell line (*Trichoplusia ni*)            *High Five*                                               Thermo Fisher Scientific    RRID:[CVCL_C190](https://scicrunch.org/resolver/CVCL_C190)               Maintained in Sf-900 II SFM

  Antibody                                 Rabbit polyclonal antibodies against StrepII              Abcam                       RRID:[AB_76949](https://scicrunch.org/resolver/AB_76949)                 one in 3000 dilution

  Antibody                                 Rabbit polyclonal antibodies against FANCI                Abcam                       RRID:[AB_74332](https://scicrunch.org/resolver/AB_74332)                 one in 3000 dilution

  Antibody                                 Rabbit polyclonal antibodies against FANCD2               Abcam                       RRID:[AB_10862535](https://scicrunch.org/resolver/AB_10862535)           one in 3000 dilution

  Antibody                                 Mouse monoclonal antibodies against FLAG                  Aviva Biosciences           RRID:[AB_10884242](https://scicrunch.org/resolver/AB_10884242)           one in 3000 dilution

  Peptide, recombinant protein             FLAG peptide                                              Sigma-Aldrich               F3290                                                                    

  Peptide, recombinant protein             Recombinant Human His6-Ubiquitin E1 Enzyme carrier free   Boston Biochem              E-304--050                                                               

  Peptide, recombinant protein             Ubiquitin and associated mutant variants                  Boston Biochem              U-110H, UM-I44A, UM-D58A, UM-F4A, UM-L73P, UM-K11R                       

  Commercial assay or kit                  TNT T7 Quick Coupled Transcription/Translation System     Promega Corporation         L1170                                                                    

  Commercial assay or kit                  Anti-FLAG-M2 affinity gel                                 Sigma Aldrich               RRID:[AB_10063035](https://scicrunch.org/resolver/AB_10063035)           

  Chemical compound, drug                  EasyTagL-\[35S\]-Methionine                               PerkinElmer Life Sciences   NEG709A500UC                                                             

  Software, algorithm                      XMIPP                                                     ([@bib6])                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protein purification {#s4-1}
--------------------

Flag-FANCI and StrepII-FANCD2 were expressed using the pFastBac1 vector (Life Technologies). For FANCI:FANCD2 complex, Hi5 cell pellets were resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 0.1 M NaCl, 1 mM EDTA, 10% glycerol and 1X mammalian protease inhibitor), and sonicated. Lysates were clarified by centrifugation at 20,000 g and the supernatants were incubated with M2 anti-FLAG agarose resin for 2 hr. The resin was washed 5 × 5 min incubation with wash buffer (20 mM Tris-HCl pH 8.0, 0.1 M NaCl, 10% glycerol), and the protein was eluted in the same buffer containing 100 μg/mL FLAG peptide. GST-UBE2T, Flag-BL100, MBP-CEF were purified as described ([@bib66]). Ubiquitin and His-UBE1 were purchased from Boston Biochem.

Biotinylated-Avi-ubiquitin purification {#s4-2}
---------------------------------------

His-Avi-ubiquitin was purified as described in [@bib59].

In vitro ubiquitination assay {#s4-3}
-----------------------------

Standard ubiquitination reactions contained 10 μM recombinant human avidin-biotin-ubiquitin, 50 nM human recombinant UBE1, 100 nM UBE2T, 100 nM PUC19 plasmid, 2 mM ATP, 100 nM FANCI:FANCD2 complex wild type (WT) or ubiquitination-deficient (KR), in reaction buffer (50 mM Tris-HCl pH 7.4, 2.5 mM MgCl~2~, 150 mM NaCl, 0.01% Triton X-100). 20 μL reactions were set up on ice and incubated at 25°C for 90 min. Reactions were stopped by adding 10 μL NuPage LDS sample buffer and heated at 80°C for 5 min. Reactions were loaded onto 4--12% SDS PAGE and run using NuPAGE MOPS buffer and assessed by western blot analysis using Flag (Aviva Biosciences) or StrepII (Abcam) antibody.

In vitro transcription/translation pull down of ^35^S-labeled proteins {#s4-4}
----------------------------------------------------------------------

Flag-tagged FANCI:FANCD2 and monoubiquitinated FANCI:FANCD2 was prepared by incubating purified FANCI:FANCD2 or monoubiquitinated FANCI:FANCD2 on Flag beads for 2 hr followed by extensive washes in buffer A (20 mM TEA pH 8.0, 150 mM NaCl, 10% glycerol). ^35^S-labeled proteins containing UBZ or other ubiquitin domains ([Table 1](#table1){ref-type="table"}) were generated using the TNT Quick Coupled T7 Transcription/Translation System (Promega) and ^35^S-labeled methionine (Perkin Elmer). 10 μL of TNT product was incubated for 4 hr at 4°C in buffer A with 100 ng Flag-tagged FANCI:FANCD2 or monoubiquitinated FANCI:FANCD2, 20 μL of Flag-beads (Sigma-Aldrich) in a 100 μL reaction. Beads were washed five times with buffer A and resuspended in LDS loading buffer. Proteins were separated by SDS-PAGE and visualized by autoradiography.

Electrophoretic mobility shift assay {#s4-5}
------------------------------------

Oligonucleotides used to create fluorescently labeled DNA were IRDYE-700-labeled X0m1 (IDTDNA) and other oligos with the sequences shown in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Assembly of the different DNA structures was performed exactly as previously described ([Supplementary file 1](#supp1){ref-type="supplementary-material"}; [@bib66]). 25 nM DNA substrates were incubated in 20 μL ubiquitination buffer containing 100 nM FANCI:FANCD2, 100 nM BL100, 100 nM CEF, 10 uM HA-ubiquitin (Boston Biochem), 50 nM UBE1 (Boston Biochem) and 100 nM UBE2T at room temperature for 90 min to initiate ubiquitination. The reaction was resolved by electrophoresis through a 6% non-denaturing polyacrylamide gel in TBE (100 mM Tris, 90 mM boric acid, 1 mM EDTA) buffer and visualized by Licor Odyssey system.

Purification of monoubiquitinated FANCI:FANCD2 complex {#s4-6}
------------------------------------------------------

Di-monoubiquitinated FANCI:FANCD2 complex was purified as described ([@bib59]). DNA molecules of 60 bp or 150 bp (dsDNA from oligonucleotides) or 2.6 kb (circular plasmid DNA) were used to stimulate the reaction for different experiments, as indicated.

Mass spectrometry analysis of monoubiquitinated FANCI:FANCD2 complex {#s4-7}
--------------------------------------------------------------------

Gels containing monoubiquitinated FANCI and FANCD2 bands were excised and in-gel digested with trypsin and subjected to LC/MS analysis on ESI-FTICR mass spectrometer at Bio21, The University of Melbourne. The analysis program MASCOT was used to identify ubiquitination sites on FANCI and FANCD2.

Negative stain electron microscopy {#s4-8}
----------------------------------

Freshly purified monoubiquitinated or non-ubiquitinated FANCI:FANCD2 complex was applied to glow-discharged, carbon/formvar grids and allowed to adsorb for 60 s. Specimen was then stained with 2% uranyl formate for 60 s. Specimen were imaged at a magnification of 73,000 x on a Ceta camera (corresponding to a pixel size of 1.9 Å) in Talos 120 kV. For FANCI:FANCD2 complex, 20 micrographs were analyzed and 4553 particles were picked for 2D classification. For monoubiquitinated FANCI:FANCD2 complex, 20 micrographs were analyzed and 4698 particles were picked for 2D classification. The length and width of 2D class average were measured using ImageJ.

Single-particle image processing {#s4-9}
--------------------------------

Monoubiquitinated or non-ubiquitinated FANCI:FANCD2 particles were semi-automatically picked using XMIPP3 (83). The parameters of the contrast transfer function (CTF) for negative stained data was estimated on each micrograph using CTFFIND3 ([@bib35]). Finally, reference free 2D alignment and averaging were executed using XMIPP3.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The authors reconstituted FANCI:FANCD2 ubiquitination by the FA core complex in vitro, and found that monoubiquitination of FANCD2 stabilizes FANCI:FANCD2 heterodimers on dsDNA, and that the purified monoubiquitinated FANCI:FANCD2 forms filamentous arrays in dsDNA. These findings provide some important insights in the role of monoubiquitination of the FANCI:FANCD2 complex in the regulation of the FA pathway.

**Decision letter after peer review:**

Thank you for submitting your article \"Monoubiquitination by the Fanconi Anemia core complex locks FANCI:FANCD2 on DNA in filamentous arrays\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and John Kuriyan as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Thank you for sending your manuscript entitled \'Monoubiquitination by the Fanconi Anemia core complex locks FANCI:FANCD2 on DNA in filamentous arrays\' to *eLife*. Your submission was reviewed by three experts in the field, and there is a strong consensus that your study reports significant progress in our understanding of the structure and function of the FANC core complex and has the potential to make a significant impact. However, the reviewers also felt that additional experimentation and analysis is required prior to final acceptance.

Essential revisions:

1\) The description of the protocol for FANCI-FANCD2 complex formation requires more information on the exact experimental protocol and detail.

2\) More evidence for filament formation by FANCI-FANCD2 is needed to distinguish a filament from other types of oligomeric structures.

For example, biochemical experiments could provide evidence for filament formation. Under conditions of excess DNA, do several protein complexes bind to a single DNA (indicative of a preference of filament formation)? Are there indications of cooperativity?

In addition, it seems that more structural analysis could address this issue. Perhaps 2D averaging of the ID2 filaments could be attempted (since the authors already have made negative stain grids and would probably just need to collect more data). If a repeating unit emerges from the 2D analysis, this would provide a strong argument that the nucleoprotein complex observed is actually composed of a structured filament. This should be tried, but a negative result would not preclude publication.

3\) Figure 1 is missing a control of no IDs-complex control for the pull downs.

4\) Figure 3: Figure 3, 4th panel from the left: quantification of% DNA bound seems strange. In the gel picture, significant amount of ID2:DNA complex is visible in I/D2 and I-KR/D2-KR lanes, which suggest that this type of DNAs can bind to I:D2 complex even in the absence of ubiquitination. The authors should mention this and show how to interpret this.

5\) Figure 4D: Quality of the FANCI blot in this figure is poor, and it is difficult to interpret this data. The result of ID2:dsDNA complex formation shown in Figure 4D is not consistent with the result shown in Figure 4C. (In Figure 4C, less ID2:dsDNA complex is seen in I-WT/D2-KR compared to in I-KR/D2-WT, but in Figure 4D, more ID2:dsDNA complex is seen in I-WT/D2-KR compared to in I-KR/D2-WT.)

6\) Figure 8: \"reduce the size of ID2 in an X but not Y direction\" needs quantification.

10.7554/eLife.54128.sa2

Author response

> Essential revisions:
>
> 1\) The description of the protocol for FANCI-FANCD2 complex formation requires more information on the exact experimental protocol and detail.

The purification for monoubiquitinated FANCI-FANCD2 and other protein complexes are described in our Avi-Ubiquitin paper just published in PLoS One, Tan et al., 2020. A citation to this paper is now included in the manuscript.

In addition, we have provided a key resource table has been added at the start of the Materials and methods section.

> 2\) More evidence for filament formation by FANCI-FANCD2 is needed to distinguish a filament from other types of oligomeric structures. For example, biochemical experiments could provide evidence for filament formation.

We have attempted several EM and biochemistry approaches but cannot prove that what we see are ordered filaments:

-- Fast Fourier Transformation of the EM images does not reveal clear evidence for layer lines, that are expected for fiber diffraction;

-- Examination of the power-spectrum relating to boxed-out individual arrays does not reveal evidence of repeating pattern;

-- Class averaging of the arrays reveals no evidence of order.

We conclude the I^Ub^D2^Ub^ arrays are probably not true filaments like RAD51/RecA, but more like RPA or SSB, which coat DNA in a cooperative manner but do not form true ordered "filaments". As such, we have chosen to describe them in this manuscript as "filament-like" or "filamentous arrays". It will be a major focus of our research group (and others) to follow up on the structure of these arrays and identify mutants or conditions in which array formation is promoted and required. We also think that cryo-EM will be useful to prove whether they are ordered and/or filaments. While obtaining such a dataset is outside the scope of the current manuscript, we have still revealed two novel properties of ubiquitinated-FANCI:FANCD2 complex: DNA clamping (renamed from "locking"), and a higher order structure that coats DNA. As highlighted in the Discussion, these two findings elucidate many unexplained phenomena relating to the Fanconi Anemia pathway and will stimulate a large amount of further research.

> Under conditions of excess DNA, do several protein complexes bind to a single DNA (indicative of a preference of filament formation)? Are there indications of cooperativity?

All of the experiments as presented are performed under conditions of excess DNA, so the existence of "arrays" on shorter (150bp) and longer (plasmid) DNA supports the idea of cooperativity. Using our system, it is not a trivial task to perform true cooperativity experiments under properly controlled conditions, because there are so many components. Cooperativity of binding can be measured for something like RAD51 because it is one protein, requiring no rate-limiting modification for DNA binding. But with our system, changing one of DNA, FA core, ID2, and other enzymatic components has indirect effects on all the other components, for example the rate of ubiquitination, that confound the findings of bulk experiments. Instead, we are in the process of establishing a single-molecule system for the observation of individual ID2 particles and their location on a fluorescent DNA molecule prior to and after monoubiquitination. This will allow us, at some time in the future, to elucidate direct observation of cooperativity, but remains a "non-core" part of the findings described in the present manuscript.

> In addition, it seems that more structural analysis could address this issue. Perhaps 2D averaging of the ID2 filaments could be attempted (since the authors already have made negative stain grids and would probably just need to collect more data). If a repeating unit emerges from the 2D analysis, this would provide a strong argument that the nucleoprotein complex observed is actually composed of a structured filament. This should be tried, but a negative result would not preclude publication.

As mentioned above, we have attempted for a very long time to 2D averaging the ID2 filaments. The main issue is that the filaments are neither "straight" nor "helical", thus impeding structural analysis. A very similar problem has been encountered by researchers attempting to structurally characterise filamentous arrays of replication protein A (RPA) on DNA (e.g. see Yates et al., 2018).

> 3\) Figure 1 is missing a control of no IDs-complex control for the pull downs.

We observe no pulldown of any of the proteins tested using only Flag-affinity resin. This data has now been included in Figure 1.

> 4\) Figure 3: Figure 3, 4th panel from the left: quantification of% DNA bound seems strange. In the gel picture, significant amount of ID2:DNA complex is visible in I/D2 and I-KR/D2-KR lanes, which suggest that this type of DNAs can bind to I:D2 complex even in the absence of ubiquitination. The authors should mention this and show how to interpret this.

Thank you for highlighting this observation. We previously observed that 3'Flap DNA was able to stimulate FANCD2 monoubiquitination more strongly than 5'Flap DNA (van Twest et al., 2017), and other studies have also seen increased binding preference for non-ubiquitinated ID2 to 3'Flap (e.g. Joo et al., 2011). We have added more information in the text. We have added this text to the Results: "Interestingly, non-ubiquitinated ID2 also exhibited high affinity towards 3' flap DNA structure (similar to a replication fork stalled on the lagging strand), which has been previously observed (Liang et al., 2016). The 3'-Flap structure, and each of the other dsDNA containing structures, led to increased ID2 monoubiquitination and increased retention of an EMSA shifted band (Figure 3)."

> 5\) Figure 4D: Quality of the FANCI blot in this figure is poor, and it is difficult to interpret this data. The result of ID2:dsDNA complex formation shown in Figure 4D is not consistent with the result shown in Figure 4C. (In Figure 4C, less ID2:dsDNA complex is seen in I-WT/D2-KR compared to in I-KR/D2-WT, but in Figure 4D, more ID2:dsDNA complex is seen in I-WT/D2-KR compared to in I-KR/D2-WT.)

The FANCI western blot in Figure 4D is now updated with better resolution. The difference in Figure 4D was due to higher protein concentration used for western blot imaging. Figure 4 legend is now updated with the correct protein concentration.

> 6\) Figure 8: \"reduce the size of ID2 in an X but not Y direction\" needs quantification.

X and Y direction of ID2 and I^ub^D2^ub^ 2D classes are measured and shown in Figure 8C.
